norharman has been researched along with lazabemide in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Baek, SC; Cho, ML; Kang, MG; Kim, H; Lee, H; Oh, SR; Park, D; Ryu, HW | 1 |
Asensio, VJ; Esteban, S; GarcĂa-Sevilla, JA; Miralles, A; Moranta, D; Sastre-Coll, A | 1 |
2 other study(ies) available for norharman and lazabemide
Article | Year |
---|---|
Selective inhibition of monoamine oxidase A by chelerythrine, an isoquinoline alkaloid.
Topics: Benzophenanthridines; Dose-Response Relationship, Drug; Humans; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship | 2018 |
High-affinity binding of beta-carbolines to imidazoline I2B receptors and MAO-A in rat tissues: norharman blocks the effect of morphine withdrawal on DOPA/noradrenaline synthesis in the brain.
Topics: Animals; Benzofurans; Binding, Competitive; Brain; Carbolines; Cerebral Cortex; Dihydroxyphenylalanine; Dose-Response Relationship, Drug; Harmine; Hippocampus; Imidazoles; Imidazoline Receptors; Liver; Male; Monoamine Oxidase; Morphine; Morphine Dependence; Naloxone; Norepinephrine; Picolinic Acids; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Drug; Substance Withdrawal Syndrome; Thiazoles; Tritium; Tyrosine 3-Monooxygenase | 2005 |